Everything below concerns HPLC-UV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Target validation (TV) → Assay development → High-throughput screening (HTS) → Hit to lead (H2L) → Lead optimization (LO) → Preclinical development → Clinical development The hit to lead stage starts with confirmation and evaluation of the initial screening hits and is followed by synthesis of analogs (hit expansion). Typically the initial screening hits display binding affinities for their biological target in the micromolar (10−6 molar concentration) range. Through limited H2L optimization, the affinities of the hits are often improved by several orders of magnitude to the nanomolar (10−9 M) range. The hits also undergo limited optimization to improve metabolic half life so that the compounds can be tested in animal models of disease and also to improve selectivity against other biological targets binding that may result in undesirable side effects. On average, only one in every 5,000 compounds that enters drug discovery to the stage of preclinical development becomes an approved drug.
A number of former Wildcats have gone on to pursue successful professional NBA careers (especially during the Lute Olson era), including Gilbert Arenas, Richard Jefferson, Mike Bibby, Jason Terry, Sean Elliott, Damon Stoudamire, Khalid Reeves, Luke Walton, Hassan Adams, Salim Stoudamire, Andre Iguodala, Channing Frye, Brian Williams (later known as Bison Dele), Sean Rooks, Jud Buechler, Michael Dickerson, Chase Budinger, Jordan Hill, Jerryd Bayless, Derrick Williams, Kadeem Allen, Aaron Gordon, Solomon Hill, Rondae Hollis-Jefferson, Stanley Johnson, T.J McConnell, Lauri Elias Markkanen, Kobi Simmons, Steve Kerr, Deandre Ayton, Rawle Alkins, and Allonzo Trier. Kenny Lofton, now best known as a former Major League Baseball star, was a four-year letter winner as a Wildcat basketball player (and was on the 1988 Final Four team), before one year on the Arizona baseball team. Another notable former Wildcat basketball player is Eugene Edgerson, who played on the 1997 and 2001 Final Four squads, and spent some of his professional careers as one of the Harlem Globetrotters as "Wildkat" Edgerson.
== Academic career == Following his Ph.D. degree research into the pharmacokinetics of amphetamines, he took up a postdoctoral research appointment in the laboratory of Sidney Riegelman, School of Pharmacy, University of California, San Francisco (1965-1967), studying the pharmacokinetics of aspirin, and then took up a faculty position there (1967–75). While at UCSF. Rowland became a member of the joint Pharmacy-Medicine NIGMS funded program in Clinical Pharmacology, and moved his research from a prevailing descriptive approach to a more mechanistic, physiologically-based one, including the clearance concept that helped lay the foundations of modern pharmacokinetics. Together with Riegelman and Leslie Benet he founded the Journal of Pharmacokinetics and Biopharmaceutics (1973) (renamed Journal of Pharmacokinetics and Pharmacodynamics, 2001), and was a senior editor of it until 2007. In 1975 Rowland returned to the United Kingdom to take up a position of Professor of Pharmacy, University of Manchester where he extended his research on physiologically based pharmacokinetics including development of an in silico method for predicting tissue distribution of drugs based on tissue composition and physicochemical properties. In 1983 he founded Medeval, undertaking early stage clinical evaluation of new medicines under development. Together with Brian Houston and Leon Aarons he established the Centre for Applied Pharmacokinetic Research (1996). He has promoted the application of microdosing in clinical drug development.
A field ration (known under a variety of other names) is a military ration intended to provide nutrition and sustenance in the field, in combat, at the front line, or where eating facilities are otherwise unavailable. Field rations can be categorized into two main types:
Sources: en.wikipedia.org
=== Pregnancy === HLA-G plays a role in immune tolerance in pregnancy, being expressed in the placenta by extravillous trophoblast cells (EVT), while the classical MHC class I genes (HLA-A and HLA-B) are not. As HLA-G was first identified in placenta samples, many studies have evaluated its role in pregnancy disorders, such as preeclampsia and recurrent pregnancy loss. Its downregulation is related to HLA-A and -B downregulation results in protection from cytotoxic T cell responses, but would in theory result in a missing self response by natural killer cells. HLA-G is a ligand for natural killer (NK) cell inhibitory receptor KIR2DL4, and therefore expression of this HLA by the trophoblast defends it against NK cell-mediated death. The presence of soluble HLA-G (sHLA-G) in embryos is associated with better pregnancy rates. In order to optimize pregnancy rates, there is significant evidence that a morphological scoring system is the best strategy for the selection of embryos. However, presence of soluble HLA-G might be considered as a second parameter if a choice has to be made between embryos of morphologically equal quality.
== Further reading == Müller, Bodo (2006). Coatings formulation: an international textbook. Urlich Poth. Hannover: Vincentz. ISBN 3-87870-177-2. OCLC 76886114. Spyrou, Emmanouil (2012). Powder coatings chemistry and technology (3 ed.). Vincentz Network. ISBN 978-3-86630-884-8. OCLC 828194496. Titanium and titanium alloys, edited by C. Leyens and M. Peters, Wiley-VCH, ISBN 3-527-30534-3, table 6.2: overview of several coating systems and fabrication processes for titanium alloys and titanium aluminides (amended) Coating Materials for Electronic Applications: Polymers, Processes, Reliability, Testing by James J. Licari; William Andrew Publishing, Elsevier, ISBN 0-8155-1492-1 High-Performance Organic Coatings, ed. AS Khanna, Elsevier BV, 2015, ISBN 978-1-84569-265-0
Genes express their functional effect through the production of proteins, which are molecules responsible for most functions in the cell. Proteins are made up of one or more polypeptide chains, each composed of a sequence of amino acids. The DNA sequence of a gene is used to produce a specific amino acid sequence. This process begins with the production of an RNA molecule with a sequence matching the gene's DNA sequence, a process called transcription. This messenger RNA molecule then serves to produce a corresponding amino acid sequence through a process called translation. Each group of three nucleotides in the sequence, called a codon, corresponds either to one of the twenty possible amino acids in a protein or an instruction to end the amino acid sequence; this correspondence is called the genetic code. The flow of information is unidirectional: information is transferred from nucleotide sequences into the amino acid sequence of proteins, but it never transfers from protein back into the sequence of DNA—a phenomenon Francis Crick called the central dogma of molecular biology. The specific sequence of amino acids results in a unique three-dimensional structure for that protein, and the three-dimensional structures of proteins are related to their functions. Some are simple structural molecules, like the fibers formed by the protein collagen. Proteins can bind to other proteins and simple molecules, sometimes acting as enzymes by facilitating chemical reactions within the bound molecules (without changing the structure of the protein itself).
On 11 December 1878, with the intent of instigating a war with the Zulu, Sir Henry Bartle Frere, on his own initiative and without the approval of the British government, presented an ultimatum to the Zulu king Cetshwayo in terms with which he could not possibly comply: that the Zulu army be disbanded and the Zulus accept a British resident. British forces crossed the Tugela river at the end of December 1878. Initially, the British suffered a heavy defeat at the Battle of Isandlwana on 22 January 1879 where the Zulu army killed more than 1,000 British soldiers in a single day. The Zulu deployment at Isandhlwana showed the well-organized tactical system that had made the Zulu kingdom successful for many decades. This constituted the worst defeat the British army had ever suffered at the hands of a native African fighting force. The defeat prompted a redirection of the war effort, and the British, though outnumbered, began winning small engagements and later larger setpiece encounters. The fighting culminated in the Siege of Ulundi, the Zulus' capital city, and the subsequent defeat of the Zulu Kingdom.
The four substrates of this enzyme are 7-methylxanthine, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are xanthine, oxidised NAD+, water, and formaldehyde. The enzyme is a non-heme iron protein that is part of the pathway of caffeine degradation in Pseudomonas putida.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.